DocGo 2025 Q3 Earnings Severe Net Loss Expansion of 752.4% Amid Revenue Decline

Monday, Nov 10, 2025 11:20 pm ET1min read
DCGO--
Aime RobotAime Summary

- DocGoDCGO-- reported a $0.28/share Q3 2025 loss (vs. $0.05 profit in 2024) with $70.81M revenue (-48.9% YoY), citing migrant program wind-down and strategic investments.

- Transportation Services drove 70.81M revenue, while Mobile Health Services contributed $20.69M, with corporate segment reporting $0 revenue excluding migrant-related income.

- CEO emphasized core business growth through SteadyMD acquisition and virtual care expansion, targeting 2026 profitability as EBITDA-negative segments improve.

- Zacks assigned a #3 (Hold) rating amid mixed post-earnings performance, reflecting investor uncertainty about short-term recovery despite long-term strategic focus.

DocGo (DCGO) reported Q3 2025 earnings on Nov 10, 2025, . $0.05 profit in 2024) and $70.81M revenue (down 48.9% YoY). , citing migrant program wind-down and strategic investments.

Revenue

DocGo’s third-quarter revenue of $70.81 million was driven by Transportation Services, , while Mobile Health Services accounted for $20.69 million. The Corporate segment reported $0 revenue, . Excluding migrant-related revenue, .

Earnings/Net Income

The company swung to a $0.28 per-share loss in Q3 2025 (vs. $0.05 profit in Q3 2024), . . , underscoring the severity of the financial downturn.

Post-Earnings Price Action Review

, . The mixed performance reflects investor uncertainty about short-term recovery amid management’s long-term optimism.

CEO Commentary

CEO emphasized record volumes in core businesses, driven by long-term medical transportation contracts and the SteadyMD acquisition. Strategic priorities include scaling virtual care and achieving 2026 profitability as EBITDA-negative segments improve.

Guidance

. , .

Additional News

  1. M&A Activity: DocGoDCGO-- acquired SteadyMD, , to enhance scalability and integrate virtual and in-person services.

  2. Strategic Expansion.

  3. Investor Outlook: Zacks Investment Research assigned DocGo a #3 (Hold) rating, .

DocGo’s Q3 results highlight a challenging transition phase, with significant revenue contraction offset by long-term growth strategies. The acquisition of SteadyMD and focus on core business expansion signal intent to rebuild momentum, though near-term profitability remains uncertain.

Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet